In fact, Rituximab has been shown to upregulate RKIP and sensitize non-Hodgkin's lymphoma cells to chemotherapeutic-induced apoptosis [32], and nitric oxide [33] and proteasome inhibitor NPI-0052 [23] have been reported to increase tumor cell sensitivity to chemo-immunotherapeutics via inducing RKIP expression and then inhibiting anti-apoptotic pathways. Here, PEBP1 is linked to non-Hodgkin lymphoma.